Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacokinetics

Background:

• Procainamide (PA) is an antiarrhythmic drug metabolized to N-acetylprocainamide (NAPA).
• Understanding the pharmacokinetic differences between PA and NAPA is crucial for optimizing therapeutic use and managing potential toxicity.

Purpose of the Study:

• To compare the pharmacokinetic profiles of procainamide (PA) and N-acetylprocainamide (NAPA) in normal subjects.
• To elucidate the distribution, elimination, and renal clearance pathways for both PA and NAPA.

Main Methods:

• Simultaneous intravenous administration of procainamide (PA) and N-acetylprocainamide labeled with Carbon-13 (NAPA-13C).
• Pharmacokinetic modeling using a 3-compartment mamillary system to analyze distribution kinetics.
• Measurement of elimination half-life (t1/2), total elimination clearance, and renal clearance.

Main Results:

• Steady-state distribution volumes for PA and NAPA were not significantly different (1.41 L/kg and 1.46 L/kg, respectively).
• NAPA exhibited slower intercompartmental clearances, a longer elimination half-life (6.2 hr vs. 2.5 hr for PA), and lower total elimination clearance (233.7 ml/min vs. 589.8 ml/min for PA).
• Renal clearances for both PA and NAPA exceeded glomerular filtration rates, indicating renal tubular secretion as a significant elimination pathway.

Conclusions:

• N-acetylprocainamide (NAPA) has a distinct pharmacokinetic profile compared to procainamide (PA), characterized by slower distribution and elimination.
• Both procainamide and N-acetylprocainamide are subject to renal tubular secretion for elimination.
• The rapid acetylator phenotype observed suggests efficient conversion of PA to NAPA in the studied subjects.